Study of JKN2501 in healthy volunteers
Part of Infections, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new drug called JKN2501 in healthy people to find the best and safest dose. It is the first time this drug is being given to humans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- Your body mass index (BMI) is between 19 and 26.
- You weigh at least 50 kg (110 lbs) if male or 45 kg (99 lbs) if female.
- You are generally healthy based on medical history and basic tests.
- You agree to use effective birth control from now until 90 days after the last dose.
- You have not used any medications or supplements in the past 2 weeks without approval.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the safety of a new drug called KT-579 in healthy adults. It is the first time this drug is being given to humans. The study will help doctors understand how the drug works in the body and if it is safe.
This early-stage trial tests a new medicine called JMT206 in healthy people to see if it is safe and how the body handles it. Healthy volunteers, ages 18 to 60, are needed to help researchers learn about the drug's effects and how it moves through the body.
This trial tests how a new drug (JMKX003142) interacts with other substances in healthy volunteers. It helps researchers understand how the drug is absorbed and processed, which is a key step before it can be tested in patients.
This trial tests a new drug called AK0610 in healthy volunteers aged 18 to 50. It helps researchers understand how the drug works in the body and whether it is safe before moving to larger studies.
This early-phase study tests a new drug in healthy volunteers to see how safe it is and how the body processes it. It helps doctors decide the right dose for future studies.
This trial tests a new oral medication, KT-621, given as different tablet or capsule forms. It helps researchers understand how the body handles the drug, which is the first step toward future treatments.
Hear when a new Bacterial Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.